Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing

Drug Is Second Asset Under Companies' Partnership

 
• By Anju Ghangurde, Vibha Ravi, Dexter Jie Yan, Joseph Haas, and Ian Haydock

Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.

Asia Deal Watch
• Source: Alamy

More from Deals

More from Business